Title : A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Pub. Date : 2017 Oct

PMID : 28424891






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric inhibitor of MEK1/2, a component of the RAS/RAF/MEK/ERK pathway which is constitutively activated in many cancers. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens
2 Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric inhibitor of MEK1/2, a component of the RAS/RAF/MEK/ERK pathway which is constitutively activated in many cancers. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens
3 Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric inhibitor of MEK1/2, a component of the RAS/RAF/MEK/ERK pathway which is constitutively activated in many cancers. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens